Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nektar

Wall Street is Overlooking This Penny Stock, Says Analyst

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

Barchart

Pink Floyd legend David Gilmour is on the cover of the new issue of Prog, on sale now!

Plus Focus, Gryphon, Tim Bowness, Leprous, Yes, Saucerful Of Secrets, Jadis, ELO, Caligula's Horse, Azure and loads more...

Louder

Nektar unveil new drummer on upcoming album Mission To Mars

UK prog legends Nektar will play their last ever UK and EWurope show at those year's Nene Valley Rock Festival in September

Louder

From analysis to the latest developments in health,
read the most diverse news in one place.

“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD set

Cult 70s proggers’ absorbing sixth album presented at its fullest.

Louder

“There was an amazing synergy. The longest single session was 72 hours. We fed the engineer speed pills… we’d scramble to write lyrics then pluck vocal harmonies out of the air”: How Nektar’s ambition and effort gave the world Remember The Future

The Bluebird character was invented at the same time by different creatives, a technical issue nearly killed off the recorded musical energy – and drugs fuelled almost every aspect of the production. But the resulting environment-themed epic was worth all the hard graft

Louder

Nektar to play final UK live show at Nene Valley Rock festival in September

UK prog legends Nektar will also release Journey to the Other Side – Live at The Dunellen Theatre in April

Louder

Nektar's Panorama CS12 controller lets you get hands-on with Logic Pro: "CS12 is a completely new take on the DAW controller"

This dedicated control surface for Apple's flagship DAW promises to make your music-making experience more tactile and immediate

MusicRadar

Read news from The Economist, FT, and more,
with one subscription

"We've got a problem with the other band who registered the name and are trying to stop us from going to Germany. But we are trying to deal with that now": How Nektar resurrected themselves with The Other Side

How the UK prog legends took on a surrogate German line-up and reclaimed their prog drown with new album The Other Side

Louder

We celebrate the 80s prog revival on the cover of the new issue of Prog, which is on sale now!

Plus Greg Lake, Yes, Nektar, Francis Dunnery, Moon Safari, Cyan, Tarja, Mariusz Duda, Earthside, Matt Berry and loads more...

Louder

“An underprized classic… with new mixes enhancing rather than simply fiddling with the original”: 50th anniversary version of Nektar’s Remember The Future

Fourth album features a bonkers storyline told through a single piece of music that ebbs and flows

Louder

6 of the best new controllers and sequencers in 2023

Ableton's vastly reimagined third iteration of Push takes the top spot this year, but who else made our shortlist?

MusicRadar

"It's the ultimate Nektar feelgood track, because everyone – onstage and in the crowd – loves it so much”: the late Roye Albrighton’s six favourite songs to play

Live performance was an essential part of enjoying his own band’s work

Louder

The 10 best covers by Iron Maiden

From 70s hard rock anthems to mystical prog deep cuts, Iron Maiden are the kings of the cover versions

Metal Hammer

How secretly embracing English glam rockers The Sweet put Scorpions on the launch pad to global stardom

In 1975 Scorpions released a German language version of Sweet's Fox On The Run under a different band name: it played a little-known but vitally important part in their rise

Metal Hammer

Get all your
news in one place.

100’s of premium titles.
One news app.

MusicRadar

Nektar Aruba review

Sprucing up its MIDI drum controller with a raft of new features, Aruba offers a slick new way of performing your software drum instruments

MusicRadar

Nektar keyboards have more features and DAW control than you thought possible

Expand creativity with a keyboard that’s part of your DAW

MusicRadar

Essential new MIDI controllers for 2023

GEAR EXPO 2023: The best devices coming out this year to take back control of your hardware and software

MusicRadar

NAMM 2023: The best new music tech gear of the show

Our top synth, monitor, controller, interface, groovebox and plugin picks

Get all your
news in one place.

100’s of premium titles.
One news app.

MusicRadar

NAMM 2023: With the Panorama CST MIDI controller, Nektar hopes to make music production a lot less about staring at a computer screen

Channel strip controller uses colour coding and easy mapping to make mixing more accessible and creative

Evening Standard

Healthcare companies PureTech and Nektar scrap merger plans

News of a potential merger had only come to light last Friday

Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

Nektar Therapeutics (NASDAQ:NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his position following June 2022. He will be succeeded by Brian Kotzin, Nektar's Head of…

Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Nektar Shares Are Down Almost 35%

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.

Investors Business Daily

Nektar Therapeutics Loses 60% Its Value As Bristol Myers-Paired Melanoma Test Flops

Adding Nektar's most advanced drug to Bristol Myers' Opdivo didn't improve outcomes for melanoma patients — leading NKTR stock to crash Monday.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.